In a media environment full of GLP-1 hype and misinformation, knowing where to find trustworthy, evidence-based information is itself a health skill. From primary clinical trials to physician-authored newsletters to expert podcasts, this guide curates the best resources for patients, caregivers, and healthcare professionals navigating the GLP-1 landscape.
The most authoritative GLP-1 information comes from the professional medical societies that set clinical standards, publish evidence reviews, and advocate for evidence-based prescribing. These organizations represent the physicians who prescribe GLP-1 medications and the researchers who study them — their publications are the foundation of trustworthy GLP-1 information.
The Obesity Medicine Association is the professional home for obesity medicine physicians across the United States, publishing clinical guidelines, continuing medical education, and patient-facing resources on GLP-1 treatment. Their Obesity Algorithm — updated annually — provides the most comprehensive, evidence-graded framework for GLP-1 prescribing available. OMA member publications summarize new clinical trial results, safety signals, and access developments for both prescribers and engaged patients. Their annual Obesity Medicine 2026 conference gathers the GLP-1 prescribing community. Available online to patients and providers nationwide.
Clinical Guidelines | Annual Obesity Algorithm | Prescriber EducationThe Obesity Society is the leading scientific research organization focused on obesity, publishing the peer-reviewed journal Obesity and hosting the annual ObesityWeek conference where landmark GLP-1 trial results are often first presented to the scientific community. Their ABOM board certification program (see Advocacy page) certifies obesity medicine physicians. The Obesity Society's position statements on GLP-1 medications represent the scientific consensus on appropriate use, long-term management, and population-level access policy. Increasingly publishing accessible patient-facing resources alongside their academic output.
Research Publications | ObesityWeek | Scientific ConsensusThe American Association of Clinical Endocrinology (AACE) publishes comprehensive clinical practice guidelines on the use of GLP-1 receptor agonists in Type 2 diabetes and obesity management. Their Comprehensive Type 2 Diabetes Management Algorithm provides the framework used by endocrinologists nationwide for GLP-1 prescribing decisions. AACE guidelines are particularly important for GLP-1 users managing diabetes alongside weight loss — addressing the complex interplay of insulin, GLP-1 medications, and other diabetes therapies that many GLP-1 users navigate.
Endocrinology Standards | Diabetes Management | Clinical AlgorithmsThe American Diabetes Association's Standards of Care in Diabetes — updated annually each January — is the gold standard clinical reference for GLP-1 use in diabetes management. The 2026 Standards include dedicated sections on GLP-1 receptor agonist selection, cardiovascular risk reduction (SELECT trial data), kidney protection, weight management goals, and access equity considerations. Free to access online at diabetes.org, the Standards of Care is the definitive resource for patients and providers navigating GLP-1 treatment decisions in the context of diabetes. Active ADA chapters in every US state provide local educational programming.
Annual Update | Gold Standard for GLP-1 in Diabetes | Free AccessPhysician-reviewed consumer health media translates complex clinical research into accessible, accurate information for GLP-1 patients. These publications sit between the primary research literature and social media — offering evidence-grounded content that patients can actually use to inform conversations with their healthcare providers.
Healthline and its sister publication Medical News Today are consistently rated among the most accurate consumer health media sources, with physician review panels that fact-check GLP-1 content before publication. Their dedicated Ozempic and semaglutide content hubs provide accessible explainers on dosing, side effects, clinical trial results, and access — covering everything from how GLP-1 medications work mechanistically to practical guides on managing injection day nausea. Highly readable for GLP-1 users seeking evidence-based information without navigating academic journals. Accessible nationwide via web and mobile app.
Physician-Reviewed | Dedicated GLP-1 Hub | Free AccessWebMD's GLP-1 content hub offers comprehensive, physician-reviewed coverage of Ozempic, Wegovy, Mounjaro, and Zepbound — including drug interaction checkers, dosing guides, side effect databases, and condition-specific information for diabetic and non-diabetic GLP-1 users. The WebMD Drug Interaction Checker is particularly valuable for GLP-1 users managing multiple medications — flagging potential interactions between GLP-1 medications and common supplements, blood pressure drugs, and other prescriptions. One of the most-visited health information destinations in the United States, accessible from any device nationwide.
Drug Interaction Checker | Dosing Guides | Physician-ReviewedThe New York Times has invested heavily in GLP-1 investigative journalism — publishing landmark pieces on medication access disparities, compounding pharmacy safety, the business of obesity medicine, and the social dimensions of widespread GLP-1 use. Their health reporters with deep pharmaceutical industry expertise produce context-rich coverage that goes beyond product descriptions to examine systemic issues in GLP-1 access, pricing, and clinical practice. For GLP-1 users interested in the broader policy and social context of their medications, the Times Health section provides unmatched depth. Accessible nationwide with digital subscription.
Investigative Journalism | Access & Policy Coverage | National ReachSTAT News is the specialist publication for pharmaceutical and biotech industry news — providing the most detailed, timely coverage of GLP-1 manufacturer decisions, FDA regulatory actions, clinical trial results, and healthcare system implications. For GLP-1 users who want to understand the business and regulatory environment shaping medication access, pricing, and availability, STAT News is essential reading. Their reporter roster includes former scientists and pharmaceutical industry insiders who provide technical depth unavailable in general health media. Free and premium content available nationwide via web subscription.
Pharmaceutical Specialist | FDA & Regulatory Coverage | Industry DepthLong-form audio and video content from board-certified physicians provides the depth of clinical context that brief articles cannot. These expert communicators translate complex GLP-1 pharmacology, trial data, and clinical practice into engaging formats accessible during commutes, workouts, or daily routines — serving GLP-1 users nationwide regardless of their media preferences.
Dr. Peter Attia's long-form podcast is the gold standard for evidence-based longevity and metabolic health content, with multiple episodes dedicated to GLP-1 pharmacology, clinical trial analysis, muscle preservation strategies, and the metabolic health implications of significant weight loss. Attia's background in surgery and his deep engagement with primary research literature produces a caliber of clinical analysis rarely found in consumer media. His GLP-1 episodes are frequently cited by obesity medicine physicians as exemplary patient education resources. Available free on all major podcast platforms nationwide.
Longevity Medicine | Deep Clinical Analysis | Free on All PlatformsDr. Andrew Huberman's Huberman Lab podcast covers GLP-1 mechanisms, metabolic health, and weight regulation episodes that have been accessed by millions of listeners. While not as clinically specialized as Attia's content, Huberman's episodes on dopamine, hunger signaling, and metabolic regulation provide valuable mechanistic context for understanding how GLP-1 medications work alongside behavioral interventions. His emphasis on practical tools — light exposure, exercise timing, cold exposure — complements GLP-1 pharmacotherapy well. Available free on YouTube, Spotify, and Apple Podcasts — accessible nationwide to any GLP-1 user with internet access.
Metabolic Health Episodes | Millions of Listeners | Free on YouTubeDocs Who Lift provides a practical clinical perspective on GLP-1 medications from physicians who are also serious strength athletes — making their content uniquely relevant for GLP-1 users focused on muscle preservation, resistance training, and performance during weight loss. Their episodes on protein optimization, progressive overload during caloric restriction, and body composition management on GLP-1s address questions that generalist obesity medicine content rarely covers in adequate depth. A growing following among GLP-1 users who are also committed to fitness. Available on all major podcast platforms nationwide.
Muscle Preservation Focus | Physician Hosts | Strength Training ContextSeveral board-certified endocrinologists and obesity medicine physicians have built substantial YouTube followings producing GLP-1 education content — including Dr. Idz (Dr. Idrees Mughal), Dr. Brian Yeung, and others with verified credentials. These channels offer visual explainers on GLP-1 mechanism of action, injection technique demonstrations, side effect management guides, and clinical Q&A sessions that complement text-based resources. YouTube's search and recommendation algorithms make GLP-1 content easily discoverable. Accessible free on any device nationwide — particularly valuable for visual learners and those navigating GLP-1 injection technique for the first time.
Visual Education | Injection Technique | Free YouTube | NationwideFor GLP-1 users, caregivers, and healthcare professionals who want to read the underlying clinical trial evidence directly, several free resources provide access to full-text publications and ongoing trial registrations — enabling informed, evidence-based decisions without relying on secondary interpretations.
PubMed Central (PMC) is the US National Library of Medicine's free digital archive of biomedical research — providing full-text access to many of the most important GLP-1 clinical trials including STEP 1–5 (semaglutide weight loss), SELECT (cardiovascular outcomes), SURMOUNT 1–4 (tirzepatide), and SUSTAIN (semaglutide in diabetes). Search "semaglutide" or "tirzepatide" on pubmed.ncbi.nlm.nih.gov to find hundreds of peer-reviewed publications. For GLP-1 users who want to understand the actual evidence base for their medications — not media interpretations — PubMed Central is the essential starting point. Free, accessible nationwide via any browser.
Free Full-Text | STEP & SELECT Trials | NIH Database | Nationwide AccessClinicalTrials.gov is the US registry of ongoing and completed clinical trials — enabling GLP-1 users to find active trials they may qualify to participate in, track upcoming GLP-1 research that will shape future prescribing, and access results from completed trials. Current GLP-1 trials on the registry include tirzepatide in heart failure (SUMMIT), oral semaglutide formulations, GLP-1 in NASH/MASH liver disease, pediatric obesity trials, and combinations of GLP-1 with other metabolic agents. Participating in clinical trials provides access to cutting-edge medications and contributes to the evidence base that benefits future GLP-1 patients. Trial sites are located in major academic medical centers across all 50 states.
Active Trial Finder | Nationwide Trial Sites | Free RegistryAll podcasts, newsletters, and online research databases covered in this guide are accessible to GLP-1 users in all 50 states via internet connection — from major metros like New York, Los Angeles, Chicago, Houston, and Phoenix to rural communities in every region of the country. Medical society chapters of the ADA, OMA, and Obesity Society are active in every state. Clinical trial sites recruiting GLP-1 participants are concentrated in academic medical centers including those at Harvard, Johns Hopkins, Mayo Clinic, Cleveland Clinic, UCLA, UCSF, University of Texas, University of Michigan, and dozens of other institutions nationwide.